Nature Biotechnology
23, 1047 - 1049 (2005)
doi:10.1038/nbt0905-1047
Empowering the inventor—the case of monoclonal antibodiesMike Clark
Mike Clark is at the University of Cambridge, Department of Pathology, Tennis Court Road, Cambridge CB2 1QP, UK. Although he continues to work as an academic research scientist, he is the coinventor of a number of international patents and applications, and has royalty interests in several commercial products, including alemtuzumab (Campath). mrc7@cam.ac.uk
Academic ownership of intellectual property facilitated wide dissemination and commercialization of antibody technology. Moves at the University of Cambridge to reclaim institutional IP rights should thus be treated with caution.
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated.
|
